American Aires Inc. Announces Updates on Annual Filings, Litigation and Listing Matters, Cease Trade Order, and 2024 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that further to the Company's news releases dated April 7, 2026 and April 17, 2026, it will not file its audited annual financial statements for the fiscal year ended December 31, 2025, together with the related management's discussion and analysis and CEO and CFO certifications (collectively, the "Required Filings"), because the audited financial statem
2026-05-08 6:00 PM EDT | American Aires Inc.
Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce a purchase order ("PO") financing arrangement that will establish a revolving source of dedicated capital to support the sourcing, manufacturing, and fulfillment activities of its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The financing will be offered as a non-brokered private placement o
Technology, Biotechnology, Health
2026-05-08 10:30 AM EDT | Restart Life Sciences Corp.
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the strategic expansion of its internal operations team as the Company accelerates the scaling of its "better-for-you" functional food and Consumer Packaged Goods (CPG) portfolio. To support its growth trajectory, the Company has added a specialized Project Manager to its internal leadership team. Rep
Technology, Biotechnology, Health
2026-05-08 9:00 AM EDT | Restart Life Sciences Corp.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodat
Biotechnology, Pharmaceuticals
2026-05-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the appointment of Lindsay Hamelin as an Independent Director of the Company, effective immediately. Ms. Hamelin brings over 20 years of capital markets and corporate finance experience, with a specific expertise in corporate structuring, mergers and acquisitions, and financing strategies within publi
Technology, Biotechnology, Health
2026-05-07 6:00 AM EDT | Restart Life Sciences Corp.
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026. The Company's full financial statements and related MD&A for the third
Biotechnology, Pharmaceuticals
2026-05-06 6:00 PM EDT | InMed Pharmaceuticals
Nextleaf Reports AGM Results and Expands Industry Leadership Through CCBC
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announces the results of its annual general meeting of shareholders (the "Meeting") held on April 30, 2026, in Vancouver, British Columbia, and provides an update on its continued engagement in industry advocacy initiatives supporting the advancement of B
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-05-06 9:00 AM EDT | Nextleaf Solutions Ltd.
Theralase(R) Announces $4 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and v
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 7:10 PM EDT | Theralase Technologies Inc.
Illumisoft Lighting Corp. Provides Corporate Update Following Commencement of Trading
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (the "Company" or "Illumisoft"), a Canadian public company commercializing UV-based air disinfection technologies and a leading portfolio of energy efficient commercial LED lighting products, today provided the following corporate update. TSX-V Listing and Public Company Platform On April 23, 2026, Illumisoft Lighting Corp. commenced trading on the TSX Venture Exchange
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-05-05 9:16 AM EDT | Illumisoft Lighting Corporation
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Pittsburgh
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - May 5, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced the addition of Weinstein Imaging Associates in Pittsburgh, Pennsylvania as a new clinical site in its large multi-center observational collection protocol study to advanc
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-05-05 9:00 AM EDT | Breathe BioMedical Inc.
Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce that Horizon Health ("Horizon") has purchased an additional 100 Venowave™ units. This second commercial order follows the rapid deployment and clinical success of the initial 100-unit shipment delivered to Horizon in la
Technology, Biotechnology, Health
2026-05-05 6:30 AM EDT | Therma Bright Inc.
Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to report a significant revenue milestone for April 2026, marking a period of substantial growth following the integration of Holy Crap Foods Inc. Since completing the acquisition on February 27, 2026, the Company has executed a strategic roadmap focused on stabilizing operations, optimizing channel efficiency, a
Technology, Biotechnology, Health
2026-05-05 6:00 AM EDT | Restart Life Sciences Corp.
Bachem Announces Changes to the Corporate Executive Committee
Bubendorf, Switzerland--(Newsfile Corp. - May 5, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) today announced that Torsten Wöhr, Chief Commercial Officer, has decided to pursue a new opportunity outside the company. Until a successor will be appointed, Anne-Kathrin Stoller will assume the role of Chief Commercial Officer in addition to her responsibilities as Chief Executive Officer (CEO), effective May 25, 2026. “Torsten Wöhr
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 1:08 AM EDT | Bachem Holding AG
Scryb Inc. Changes Name to NorthPalm Capital Corp. and Announces New Trading Symbols
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm Capital" or the "Company") (formerly, Scryb Inc.), is pleased to announce that further to its news release dated April 15, 2026, the Company's common shares will commence trading on the Canadian Securities Exchange under the new name, "NorthPalm Capital Corp." effective at the market open on May 7, 2026 (the "Name Change") and the trading symbol for the Company will cha
Biotechnology, Healthcare and Hospitals, Health
2026-05-04 9:41 PM EDT | NorthPalm Capital Corp.
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-04 5:22 PM EDT | Theralase Technologies Inc.
Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Mee
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-01 8:04 AM EDT | Neural Therapeutics Inc.
Three Finalists Announced for the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Bloom Burton & Co. ("Bloom Burton") is thrilled to announce the finalists for the 2026 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honours an individual who made the greatest contribution to Canada's innovative healthcare industry in the previous year. The finalists for 2026, in alphabetical order, are: Ian Mortimer, President & Chief Executive Officer, Xenon Ph
Technology, Biotechnology, Investment Banking, Health
2026-05-01 7:30 AM EDT | Bloom Burton & Co. Inc.
BYT Holdings Ltd. Anticipates Failure-to-File Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2026) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") has made an unsuccessful application to the British Columbia Securities Commission ("BCSC"), the Company's principal securities regulator in Canada, to approve a temporary management cease trade order ("MCTO") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), which, if granted, would have prohibited trading in securities of the Company by its
Technology, Biotechnology, Construction / Building, Machinery
2026-04-30 5:34 PM EDT | BYT Holdings Ltd.
Dr. Christina Rahm Recognized Nationally for Building Patent-Driven Manufacturing Behind The ROOT Brands Products
Franklin, Tennessee--(Newsfile Corp. - April 30, 2026) - Dr. Christina Rahm, scientist, inventor, and Founder and Chief Science Officer of The ROOT Brands, has received a Gold Stevie® Award in the 2026 American Business Awards® for Building and Scaling Patent-Driven Manufacturing Infrastructure (M
Biotechnology, Food / Beverages, Health
2026-04-30 4:45 PM EDT | DRC Ventures